Back to search

Switzerland· 66040002

Qtern, Filmtabletten

A saxagliptin and dapagliflozin product containing dapagliflozinum, saxagliptinum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A10BD21

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedQtern, FilmtablettenATCA10BD21REGISTER NO.66040002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Saxagliptin and dapagliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BD21 (saxagliptin and dapagliflozin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Saxagliptin and dapagliflozin · ATC A10BD21

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
dapagliflozinum, saxagliptinum
Manufacturer
AstraZeneca AG
Country
Switzerland (CH)
ATC code
A10BD21
ATC class
Saxagliptin and dapagliflozin
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680660400025
    98 Stk
    CHF 280.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Saxagliptin and dapagliflozin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All saxagliptin and dapagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Qtern
  • Liechtenstein · Qtern
  • Norway · Qtern

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1b8ef76-7ff4-4cd6-b9e0-68b1296c6b73
GET /v1/drugs/e1b8ef76-7ff4-4cd6-b9e0-68b1296c6b73?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "saxagliptinum 5 mg + dapagliflozinum 10 mg",
  "valid_from": "2017-08-01",
  "limitations": "[{\"description\":\"Zur Behandlung von erwachsenen Patienten mit einem Typ 2 Diabetes mellitus zur Verbesserung der glykämischen Kontrolle:<br>\\nIn Kombination mit Metformin zusammen mit Diät und körperlicher Aktivität, wenn mit Diät und körperlicher Aktivität in Kombination mit Metformin und 10 mg Dapagliflozin keine ausreichende Blutzuckerkontrolle erreicht wird oder wenn bereits mit der Kombination aus 10 mg Dapagliflozin und 5 mg Saxagliptin als separate Tabletten behandelt wird.<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2017-08-01\"}]",
  "galenic_form": "Filmtabl 5 mg/10 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2017-08-01",
  "self_retention_pct": 10
}

See everything about saxagliptin and dapagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.